Jean M. Franchi Sells 2,000 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CFO Jean M. Franchi sold 2,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $52.26, for a total value of $104,520.00. Following the completion of the sale, the chief financial officer now owns 67,530 shares in the company, valued at $3,529,117.80. The trade was a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Disc Medicine Stock Up 3.0%

Shares of Disc Medicine stock traded up $1.52 on Friday, reaching $51.61. 413,971 shares of the company were exchanged, compared to its average volume of 341,858. Disc Medicine, Inc. has a one year low of $30.82 and a one year high of $68.73. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -13.17 and a beta of 0.73. The company has a current ratio of 37.65, a quick ratio of 37.65 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average of $47.22 and a 200 day moving average of $52.80.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). On average, equities research analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Scotiabank boosted their target price on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. HC Wainwright restated a "buy" rating and issued a $118.00 target price on shares of Disc Medicine in a research note on Tuesday. TD Cowen began coverage on Disc Medicine in a research note on Thursday, February 27th. They set a "buy" rating on the stock. Cantor Fitzgerald upped their price objective on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. Finally, Wedbush reiterated an "outperform" rating and set a $90.00 price objective on shares of Disc Medicine in a research note on Monday, June 16th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Disc Medicine currently has an average rating of "Buy" and an average target price of $96.70.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IRON. RA Capital Management L.P. acquired a new position in shares of Disc Medicine during the 1st quarter worth approximately $78,288,000. FMR LLC increased its holdings in shares of Disc Medicine by 358.7% during the 4th quarter. FMR LLC now owns 1,866,248 shares of the company's stock worth $118,320,000 after acquiring an additional 1,459,434 shares during the last quarter. Siren L.L.C. acquired a new position in shares of Disc Medicine during the 1st quarter worth approximately $53,207,000. Wellington Management Group LLP increased its holdings in shares of Disc Medicine by 67.9% during the 1st quarter. Wellington Management Group LLP now owns 2,343,499 shares of the company's stock worth $116,331,000 after acquiring an additional 948,094 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Disc Medicine by 62.4% during the 4th quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company's stock worth $77,170,000 after acquiring an additional 467,988 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.